Through the heart and beyond: a review on ranolazine

Abstract

Ranolazine derives from piperazine and has been approved as a drug for the therapy of chronic stable angina. It acts by selectively inhibiting the late sodium inward current. Moreover, ranolazine has other metabolic features which makes it effective in other diseases as well as coronary artery ones. In this paper I make an updated review of all possible therapeutic roles of ranolazine: through cardiology and beyond.

Keywords

• Ranolazine
• chronic stable angina
• arrhytmias
• diabetes
• Pulmonary artery hypertension
• Peripheral arterial disease